



Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference

September 23, 2021

WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming Cantor Fitzgerald *Virtual Global Healthcare Conference* to be held September 27-30, 2021.

Details of the Company's participation can be found below:

Cantor Fitzgerald Virtual Global Healthcare Conference

Format: Company presentation and one-on-one investor meetings

Date: Thursday September 30, 2021

Time: 1:20 p.m. EDT

Webcast: <https://wsw.com/webcast/cantor12/ettx/2120370>

The webcast of the Company's presentation will be accessible in the [News & Events](#) section of the Entasis website at <https://www.entasistx.com/>.

About Entasis

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting *Acinetobacter baumannii* infections), zoliflodacin (targeting *Neisseria gonorrhoeae* infections), ETX0462 (targeting multiple Gram-negative pathogens including *Pseudomonas aeruginosa*) and ETX0282CPDP (targeting *Enterobacteriaceae* infections). For more information, visit www.entasistx.com.

Entasis Contacts

Company:

Kyle Dow

Entasis Therapeutics

(781) 810-0114

kyle.dow@entasistx.com

Investor Relations:

Bruce Mackle

LifeSci Advisors

(929) 469-3859

bmackle@lifesciadvisors.com



Source: Entasis Therapeutics Holdings Inc.